TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 20519679

Group type: EXPERIMENTAL
Intervention: Sequential ACT (four cycles of doxorubicin and cyclophosphamide followed by four cycles of docetaxel)
Number of subjects: 5351

Group type: COMPARATOR
Intervention: Doxorubicin-docetaxel (four cycles of doxorubicin and docetaxel)
Number of subjects: 5351

Group type: COMPARATOR
Intervention: Concurrent ACT (four cycles of doxorubicin, cyclophosphamide, and docetaxel)
Number of subjects: 5351

Group type: EXPERIMENTAL
Intervention: Sequential ACT
Number of subjects: 5351

Group type: COMPARATOR
Intervention: Doxorubicin-docetaxel
Number of subjects: 5351

Group type: COMPARATOR
Intervention: Concurrent ACT
Number of subjects: 5351

Group type: EXPERIMENTAL
Intervention: All treatment groups
Number of subjects: 5351
Study: 18442577

Group type: EXPERIMENTAL
Intervention: T3 sympathectomy
Number of subjects: 232

Group type: COMPARATOR
Intervention: T2-4 sympathectomy
Number of subjects: 232

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 232
Study: 16600674

Group type: EXPERIMENTAL
Intervention: Segmental study of the median nerve
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Median-to-radial comparative test
Number of subjects: 267

Group type: EXPERIMENTAL
Intervention: Median-to-ulnar comparative test
Number of subjects: 267

Group type: COMPARATOR
Intervention: Normal limits derived from controls
Number of subjects: 267
Study: 12780910

Group type: EXPERIMENTAL
Intervention: Low anterior resection and anastomosis
Number of subjects: 15978

Group type: COMPARATOR
Intervention: Abdomino-perineal resection
Number of subjects: 15978
Study: 10705222

Group type: EXPERIMENTAL
Intervention: Theophylline (200-600 mg/day)
Number of subjects: 48

Group type: COMPARATOR
Intervention: Control (no theophylline treatment)
Number of subjects: 48
Study: 9172875

Group type: EXPERIMENTAL
Intervention: Deltamethrin impregnated curtains
Number of subjects: 501

Group type: COMPARATOR
Intervention: Nonimpregnated curtains (Control)
Number of subjects: 501
Study: 8465772

Group type: EXPERIMENTAL
Intervention: Amiodarone 600 mg/day for 10 days, followed by 400 mg/day for 10 days, then 200 mg/day for 2 months
Number of subjects: 63

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 63

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 63
Study: 3805473

Group type: EXPERIMENTAL
Intervention: CO2 laser treatment
Number of subjects: 13

Group type: COMPARATOR
Intervention: Cold steel surgery and electrocautery
Number of subjects: 13
Study: 29935528

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group (received bupivacaine + 5 mcg dexmedetomidine)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group (received bupivacaine + the same volume of saline)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Dexmedetomidine group
Number of subjects: 90

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 90
Study: 27924459

Group type: EXPERIMENTAL
Intervention: Sunitinib 37.5 mg
Number of subjects: 171

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 171
Study: 24343824

Group type: EXPERIMENTAL
Intervention: Magnesium sulfate
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Albuterol
Number of subjects: 330

Group type: EXPERIMENTAL
Intervention: Combination of magnesium sulfate and albuterol
Number of subjects: 330
Study: 22398963

Group type: EXPERIMENTAL
Intervention: Cognitive Therapy (CT) for 12-14 weeks
Number of subjects: 523
Study: 19320802

Group type: EXPERIMENTAL
Intervention: Dental and periodontal treatments plus oral hygiene education
Number of subjects: 58

Group type: COMPARATOR
Intervention: Conventional treatment approach with only oral hygiene education
Number of subjects: 58
Study: 18097211

Group type: EXPERIMENTAL
Intervention: Informational program regarding influenza vaccine
Number of subjects: 92
Study: 15249718

Group type: EXPERIMENTAL
Intervention: Irinotecan 50 mg/m² on days 1, 8, and 15 plus carboplatin (dose escalation starting at AUC 5 mg x min/ml to AUC 6)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Dose level 1 (MTD) of irinotecan and carboplatin
Number of subjects: 16
Study: 12733372

Group type: EXPERIMENTAL
Intervention: DS 10 mg q.n. for 8 weeks (Group A)
Number of subjects: 160

Group type: EXPERIMENTAL
Intervention: Zocor 10 mg q.n. for 8 weeks (Group B)
Number of subjects: 160

Group type: COMPARATOR
Intervention: DS 10 mg q.n. for 8 weeks (Group C)
Number of subjects: 160
Study: 9853855

Group type: COMPARATOR
Intervention: Standard intrauterine insemination (IUI)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Fallopian tube sperm perfusion (FSP)
Number of subjects: 96

Group type: EXPERIMENTAL
Intervention: Clomiphene citrate/HMG
Number of subjects: 96

Group type: COMPARATOR
Intervention: Clomiphene citrate only
Number of subjects: 96
Study: 8009591

Group type: EXPERIMENTAL
Intervention: BMA 031 (50 mg administered intravenously on the day of, as well as 2 and 4 days after transplantation)
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo control
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: BMA 031
Number of subjects: 36
Study: 2623005

Group type: EXPERIMENTAL
Intervention: Caffeine (CAF) 5.5 mg/kg
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 773414

Group type: EXPERIMENTAL
Intervention: Clobetasol propionate 0.05% ointment
Number of subjects: 12

Group type: COMPARATOR
Intervention: Betamethasone valerate 0.1% ointment
Number of subjects: 12
Study: 31587084

Group type: EXPERIMENTAL
Intervention: AA homozygotes (risk A allele)
Number of subjects: 290

Group type: COMPARATOR
Intervention: G allele carriers
Number of subjects: 290
Study: 31326433

Group type: EXPERIMENTAL
Intervention: Glepaglutide 10 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glepaglutide 1 mg
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Glepaglutide (both doses)
Number of subjects: 18
Study: 26822791

Group type: EXPERIMENTAL
Intervention: Dronabinol (5 mg, twice daily)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13
Study: 25231008

Group type: EXPERIMENTAL
Intervention: salmeterol active arm
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: dropout patterns
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: disease progression
Number of subjects: 0
Study: 24062400

Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) evaluation in bone marrow samples after induction cycle 1
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) evaluation in bone marrow samples after induction cycle 2
Number of subjects: 471

Group type: EXPERIMENTAL
Intervention: Minimal Residual Disease (MRD) evaluation in bone marrow samples after consolidation therapy
Number of subjects: 471
Study: 22288153

Group type: EXPERIMENTAL
Intervention: Ladasten (15 mg)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19637398

Group type: EXPERIMENTAL
Intervention: Buspirone (15-30 mg/day)
Number of subjects: 18

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 18
Study: 22129365

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg once daily; open-label treatment for ≥24 months; dose reduction to 4 mg and re-escalation to 8 mg allowed annually
Number of subjects: 864

Group type: EXPERIMENTAL
Intervention: Fesoterodine 8 mg once daily; open-label treatment for ≥24 months
Number of subjects: 864
Study: 15872201

Group type: EXPERIMENTAL
Intervention: Amiodarone
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Sotalol
Number of subjects: 665

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Amiodarone (in patients with ischemic heart disease)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Sotalol (in patients with ischemic heart disease)
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: Both Amiodarone and Sotalol
Number of subjects: 665

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 665
Study: 12740449

Group type: EXPERIMENTAL
Intervention: Obesity prevention plus parenting support (OPPS) intervention
Number of subjects: 43

Group type: COMPARATOR
Intervention: Parenting support (PS) only
Number of subjects: 43
Study: 10541949

Group type: EXPERIMENTAL
Intervention: Fluid restriction regimen (approximately 25% less fluid prescribed)
Number of subjects: 90

Group type: COMPARATOR
Intervention: Standard fluid regimen (60 ml/kg on day 1, increasing to 150 ml/kg by day 7)
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Colloid intake
Number of subjects: 90
Study: 7775858

Group type: EXPERIMENTAL
Intervention: High-fat diet (46% fat, 38% carbohydrate) for 6 weeks
Number of subjects: 43

Group type: COMPARATOR
Intervention: Low-fat diet (24% fat, 60% carbohydrate) for 6 weeks
Number of subjects: 43
Study: 2109073

Group type: EXPERIMENTAL
Intervention: Misoprostol 100 micrograms q.i.d.
Number of subjects: 420

Group type: EXPERIMENTAL
Intervention: Misoprostol 200 micrograms q.i.d.
Number of subjects: 420

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 420
Study: 7471925

Group type: EXPERIMENTAL
Intervention: Parent-training program
Number of subjects: 19

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 19
Study: 30478067

Group type: EXPERIMENTAL
Intervention: Ticagrelor therapy for 28 days
Number of subjects: 40
Study: 29064792

Group type: EXPERIMENTAL
Intervention: Pioglitazone 15 mg once a day
Number of subjects: 50
Study: 25296247

Group type: EXPERIMENTAL
Intervention: Nicardipine
Number of subjects: 40

Group type: COMPARATOR
Intervention: Esmolol
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Study drug failure
Number of subjects: 40

Group type: EXPERIMENTAL
Intervention: Preoperative hypertension
Number of subjects: 40
Study: 24004700

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 743

Group type: COMPARATOR
Intervention: Physician chart reminder
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Mailed education/FIT
Number of subjects: 743

Group type: EXPERIMENTAL
Intervention: Mailed education/FIT plus phone call
Number of subjects: 743
Study: 21959802

Group type: EXPERIMENTAL
Intervention: PVP K90 160 mg/tablet
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PVP K90 partially replaced with different gums
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: PVP K90 and gum tragacanth
Number of subjects: 0

Group type: COMPARATOR
Intervention: Commercially available Diclofenac Sodium SR
Number of subjects: 0
Study: 17786445

Group type: EXPERIMENTAL
Intervention: Regimens containing oxaliplatin and infusional 5‐fluorouracil (5‐FU)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Irinotecan and 5‐FU
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Cetuximab combined with irinotecan
Number of subjects: 0
Study: 16541114

Group type: EXPERIMENTAL
Intervention: 0.4 mg oral daily tamsulosin (group 1, n=59)
Number of subjects: 118

Group type: COMPARATOR
Intervention: Placebo (group 2, n=59)
Number of subjects: 118
Study: 14506138

Group type: EXPERIMENTAL
Intervention: Two-weekly schedule of gemcitabine (1500 mg/m²) and cisplatin (90 mg/m²)
Number of subjects: 73

Group type: COMPARATOR
Intervention: Weekly schedule of gemcitabine and cisplatin
Number of subjects: 73

Group type: EXPERIMENTAL
Intervention: Two-weekly schedule
Number of subjects: 73

Group type: COMPARATOR
Intervention: Weekly schedule
Number of subjects: 73
Study: 11038435

Group type: COMPARATOR
Intervention: High-fat meal (fed state)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fasted state (control)
Number of subjects: 0
Study: 8850048

Group type: EXPERIMENTAL
Intervention: Topical formulations containing clobetasol propionate, doxepin hydrochloride, metronidazole, mupirocin, oxiconazole nitrate, and terbinafine hydrochloride
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Doxepin hydrochloride cream vehicle
Number of subjects: 108

Group type: EXPERIMENTAL
Intervention: Calcipotriene and ketoconazole
Number of subjects: 108
Study: 1626168

Group type: COMPARATOR
Intervention: Dolotren (D) 100 mg, administered b.i.d. for 15 days
Number of subjects: 9

Group type: EXPERIMENTAL
Intervention: Dolotren Retard (DR) 100 mg, administered once a day for 15 days
Number of subjects: 9

Group type: COMPARATOR
Intervention: Both D and DR
Number of subjects: 9
Study: 6844471

Group type: EXPERIMENTAL
Intervention: Supportive psychotherapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Analytical psychotherapy
Number of subjects: 65

Group type: EXPERIMENTAL
Intervention: Medical nurse-led psychotherapy (without training)
Number of subjects: 65

Group type: COMPARATOR
Intervention: Untreated control group
Number of subjects: 65
Study: 30243810

Group type: EXPERIMENTAL
Intervention: Expectant management
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Uterine evacuation
Number of subjects: 276

Group type: EXPERIMENTAL
Intervention: Empiric use of methotrexate
Number of subjects: 276
Study: 27631270

Group type: COMPARATOR
Intervention: Conventional ISB (ISB with the conventional approach, n=31)
Number of subjects: 92

Group type: COMPARATOR
Intervention: C5 ISB (ISB with the C5 approach, n=30)
Number of subjects: 92

Group type: EXPERIMENTAL
Intervention: Control (no ISB, n=31)
Number of subjects: 92
Study: 24146195

Group type: EXPERIMENTAL
Intervention: Flexible reinforced laryngeal mask airway (LMA)
Number of subjects: 76

Group type: COMPARATOR
Intervention: Plain endotracheal tube
Number of subjects: 76
Study: 21928871

Group type: EXPERIMENTAL
Intervention: Postevent assessment (n = 296)
Number of subjects: 492

Group type: COMPARATOR
Intervention: Control group (n = 196)
Number of subjects: 492
Study: 20430326

Group type: EXPERIMENTAL
Intervention: Initial stance width (ISW) of 0.3 body height
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Initial stance width (ISW) of 0.05 body height
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Initial stance width (ISW) of 0 body height
Number of subjects: 61
Study: 18700424

Group type: EXPERIMENTAL
Intervention: CPAP at -5 cm H2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CPAP at 0 cm H2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CPAP at +5 cm H2O
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: CPAP at +10 cm H2O
Number of subjects: 10
Study: 15882483

Group type: EXPERIMENTAL
Intervention: Fruits
Number of subjects: 47

Group type: EXPERIMENTAL
Intervention: Vegetables
Number of subjects: 47
Study: 12587887

Group type: EXPERIMENTAL
Intervention: Intermittent high-intensity warm-up (5 sprints at 200% VO2max for 10 s with 50 s recovery at 55% VO2max)
Number of subjects: 7

Group type: COMPARATOR
Intervention: Continuous warm-up (15 min at approximately 65% VO2max)
Number of subjects: 7
Study: 14601484

Group type: EXPERIMENTAL
Intervention: Cushing's syndrome (CUS)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Visceral obesity (OTY)
Number of subjects: 62

Group type: EXPERIMENTAL
Intervention: Addison's disease (AD)
Number of subjects: 62

Group type: COMPARATOR
Intervention: Healthy women (KON)
Number of subjects: 62
Study: 10201278

Group type: EXPERIMENTAL
Intervention: Desipramine
Number of subjects: 0
Study: 8519562

Group type: EXPERIMENTAL
Intervention: Guided tissue regeneration using e‐PTFE membranes (Gore‐Tex)
Number of subjects: 9

Group type: COMPARATOR
Intervention: Conventional surgery
Number of subjects: 9
Study: 2136070

Group type: EXPERIMENTAL
Intervention: Propranolol
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: Carbamazepine
Number of subjects: 80
Study: 7416612

Group type: EXPERIMENTAL
Intervention: Subcutaneously administered epinephrine
Number of subjects: 48

Group type: EXPERIMENTAL
Intervention: Inhaled isoproterenol
Number of subjects: 48

Group type: COMPARATOR
Intervention: Intravenously administered aminophylline
Number of subjects: 48
Study: 31962198

Group type: EXPERIMENTAL
Intervention: Whole breast irradiation (WBI) after endocrine therapy (ET)
Number of subjects: 869

Group type: COMPARATOR
Intervention: Endocrine therapy (ET) alone (observation)
Number of subjects: 869
Study: 31202539

Group type: EXPERIMENTAL
Intervention: LA‐FINDRISC
Number of subjects: 3061

Group type: COMPARATOR
Intervention: O‐FINDRISC
Number of subjects: 3061
Study: 28502637

Group type: EXPERIMENTAL
Intervention: Prepackaged disposable washcloths
Number of subjects: 2637

Group type: COMPARATOR
Intervention: Traditional bath basins
Number of subjects: 2637
Study: 25660465

Group type: EXPERIMENTAL
Intervention: Integrated community-based counselling intervention with two pregnancy and five postnatal home visits delivered by community health workers.
Number of subjects: 4137

Group type: COMPARATOR
Intervention: Control group (no intervention).
Number of subjects: 4137
Study: 22935028

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Cold-water immersion
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control
Number of subjects: 16
Study: 20602715

Group type: EXPERIMENTAL
Intervention: Duloxetine 60 mg once daily (QD) and increased to 120 mg QD at week 7 if < 30% pain reduction
Number of subjects: 256

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 256
Study: 19583755

Group type: EXPERIMENTAL
Intervention: General anaesthesia (GA)
Number of subjects: 104

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 104
Study: 16829208

Group type: EXPERIMENTAL
Intervention: Angiogenesis inhibitor
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chemotherapy
Number of subjects: 0
Study: 15651152

Group type: EXPERIMENTAL
Intervention: Fecal occult blood test (FOBT) screening
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Colonoscopy screening
Number of subjects: 0

Group type: COMPARATOR
Intervention: Flexible sigmoidoscopy and irigography
Number of subjects: 0
Study: 11707042

Group type: EXPERIMENTAL
Intervention: Single stage head‐up tilt table test (HUT) with infusion of 3.44 microg/kg per hour of nitroglycerin
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Conventional multistage test with infusion of nitroglycerin from 1.72 microg/kg per hour to 5.16 microg/kg per hour
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy control subjects during single stage HUT
Number of subjects: 37

Group type: COMPARATOR
Intervention: Healthy control subjects during multistage HUT
Number of subjects: 37

Group type: EXPERIMENTAL
Intervention: Duration of single stage HUT
Number of subjects: 37
Study: 9597560

Group type: EXPERIMENTAL
Intervention: 5 mg/day testosterone transdermal patch (T)
Number of subjects: 21

Group type: COMPARATOR
Intervention: 2.5 mg/day testosterone transdermal patches (R)
Number of subjects: 21
Study: 7513516

Group type: EXPERIMENTAL
Intervention: Ginkgo EGb 761 (Tebonin) + HAES
Number of subjects: 80

Group type: COMPARATOR
Intervention: Naftidrofuryl (Dusodril) + HAES
Number of subjects: 80
Study: 3280519

Group type: EXPERIMENTAL
Intervention: Closed loop method
Number of subjects: 50

Group type: COMPARATOR
Intervention: Capped syringe method
Number of subjects: 50
Study: 31240541

Group type: EXPERIMENTAL
Intervention: APAP therapy
Number of subjects: 75

Group type: COMPARATOR
Intervention: Nasal strips (control)
Number of subjects: 75
Study: 29943522

Group type: EXPERIMENTAL
Intervention: Gabapentin 800 mg
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 52
Study: 27537606

Group type: EXPERIMENTAL
Intervention: Myopic defocus group (MDG) with additional -3D lenses
Number of subjects: 51

Group type: EXPERIMENTAL
Intervention: Hyperopic defocus group (HDG) with additional +3D lenses
Number of subjects: 51

Group type: COMPARATOR
Intervention: Control group (CG) with full correction
Number of subjects: 51
Study: 25131453

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation superimposed onto voluntary contractions (NMES+; n=22)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Neuromuscular electrical stimulation (NMES; n=22)
Number of subjects: 89

Group type: EXPERIMENTAL
Intervention: Volitional contraction (VC; n=22)
Number of subjects: 89

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 89
Study: 22776011

Group type: EXPERIMENTAL
Intervention: Multicomponent intervention (ESCAPE)
Number of subjects: 26
Study: 20137138

Group type: EXPERIMENTAL
Intervention: Transfusion of mesenchymal stem cells (MSCs)
Number of subjects: 15

Group type: COMPARATOR
Intervention: Control (HSCT only)
Number of subjects: 15
Study: 18713887

Group type: EXPERIMENTAL
Intervention: Sevoflurane 2% end-tidal concentration in air/oxygen
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Co-administration of ketoprofen 1 mg/kg and fentanyl 1 microg/kg
Number of subjects: 27

Group type: COMPARATOR
Intervention: Baseline measurements before premedication with midazolam 0.1 mg/kg IV
Number of subjects: 27
Study: 15878728

Group type: EXPERIMENTAL
Intervention: Fixed sequence learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Random sequence learning
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Contralesional hand performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Ipsilesional hand performance
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Maximum tapping rate
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control participants
Number of subjects: 0
Study: 15250818

Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study: 10890862

Group type: EXPERIMENTAL
Intervention: Topical lodoxamide ophthalmic solution 0.1% (LOS)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Topical cromolyn sodium ophthalmic solution 4% (CSO)
Number of subjects: 30
Study: 8931233

Group type: EXPERIMENTAL
Intervention: New technique for acute embolus occlusion of the SMA (ligating the distal end of the SMA and using a Fogarty balloon catheter to remove clots).
Number of subjects: 3
Study: 1390326

Group type: EXPERIMENTAL
Intervention: Nitrendipine 20 mg once a day
Number of subjects: 26

Group type: COMPARATOR
Intervention: Hydrochlorothiazide 25 mg once a day
Number of subjects: 26
Study: 2996906

Group type: EXPERIMENTAL
Intervention: 400 mg pentoxifylline
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: 12 micrograms/ml pentoxifylline
Number of subjects: 6

Group type: COMPARATOR
Intervention: Matching placebo
Number of subjects: 6
Study: 3298328

Group type: EXPERIMENTAL
Intervention: Flupenthixol
Number of subjects: 0

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 0
Study: 29570579

Group type: EXPERIMENTAL
Intervention: Resisted sprint training (RST) with sled-equivalent resistive loads of ∼45% body mass
Number of subjects: 20

Group type: COMPARATOR
Intervention: Unresisted sprints (URS)
Number of subjects: 20
Study: 30325849

Group type: EXPERIMENTAL
Intervention: Hemoadsorption device (CytoSorb) used in 17 patients
Number of subjects: 35

Group type: COMPARATOR
Intervention: Control group (no hemoadsorption device used in 18 patients)
Number of subjects: 35
Study: 28611006

Group type: EXPERIMENTAL
Intervention: Atorvastatin 80mg daily for one year
Number of subjects: 200

Group type: COMPARATOR
Intervention: Atorvastatin 10mg daily for one year
Number of subjects: 200